SMAD4 and head and neck squamous cell carcinoma: A recent study has shown that olaparib (at 1 and 5 μmol/L) is effective in combination with radiation in decreasing the survival of HPV-negative HNSCC cells, but only those that are SMAD4 deficient[53].